TXMD · TherapeuticsMD, Inc. · Exempt Offerings
$1.75
-0.07 (-3.85%)
At close · Nov 5
View the 10-Q filed Aug 11, 2026
Return incl. dividend (before tax)
Q2 2022 earnings call transcript
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The potential impact of these factors in conjunction with the uncertainty of the capital markets raises substantial doubt about our ability to continue as a going concern for the next twelve months from the issuance of these financial statements.”View the 10-Q filed Aug 11, 2026
Customer concentration
— top 3 customers 100% of revenue
3 customers — 100% of revenue (the three and six months ended June 30, 2026)
“For the three and six months ended June 30, 2026, 100% of license revenue related to Mayne Pharma, Theramex and Knight.”
Market Cap
$21.07M
Shares
11.57M
Volume · Nov 5
3554
Avg daily vol (3M)
23.41K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Private capital raises reported to the SEC on Form D under Regulation D, showing the offering size, amount sold, minimum investment and number of investors. Public operating companies rarely raise capital this way, so this page is often empty.
| Filed | Type | Industry | Offering | Sold | Exemptions |
|---|---|---|---|---|---|
| 2023-07-11 | New | Pharmaceuticals | $5,000,000 | $1,149,998 | 06b |
| 2022-11-14 | New | Pharmaceuticals | $7,000,000 | $7,000,000 | 06b |
| 2022-10-17 | New | Pharmaceuticals | $7,000,000 | $7,000,000 | 06b |
| 2022-08-16 | New | Pharmaceuticals | $15,000,000 | $15,000,000 | 06b |
| 2020-08-14 | New | Pharmaceuticals | $7,500,000 | $7,500,000 | 06b |
Showing 1–5 of 5 filings